Market Overview

Why Regeneron's Growth Opportunity Is Unappreciated

Share:
Why Regeneron's Growth Opportunity Is Unappreciated

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) shares were advancing Monday following a sell-side upgrade and the news of President Donald Trump being administered its investigational COVID-19 antibody cocktail. 

The Regeneron Analyst: Cantor Fitzgerald analyst Alethia Young upgraded Regeneron shares from Neutral to Overweight and increased the price target from $624 to $690.

Related Link: The Week Ahead In Biotech: Avenue's FDA Decision, Alkermes Adcom Meeting, Aziyo Biologics IPO

The Regeneron Thesis: Regeneron shares have outperformed the broader biotech sector thanks to greater appreciation of its growth profile and a notable setback for Novartis AG's (NYSE: NVS) wet AMD treatment Beovu in the real world, Young said in a Sunday upgrade note.

The outperformance does not reflect the allergic disease drug Dupixent's prospects as a near- and long-term growth driver, the analyst said.

Cantor estimates worldwide Dupixent sales of $6.3 billion in 2021, ahead of the $5.2-billion consensus estimate.

Expansion opportunities for Dupixent in younger patients, different indications and broader geographies should also drive commercial growth in the coming years, Young said.

With antibodies expected to emerge as an important treatment and prevention option for COVID-19, Regeneron's antibody cocktail REGN-COV2 is another unappreciated near-term revenue driver in 2021, the analyst said. The regulatory path for the antibody cocktail is uncertain, she said. 

Regeneron's oncology strategy is shaping up well, with solid monotherapy PD-1 data in non-small cell lung cancer that sets the stage for future combination work that could drive mid- to long-term growth, according to Cantor Fitzgerald. 

REGN Price Target: At last check, Regeneron shares were rallying 7.11% to $604.98.

Related Link: Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates

Latest Ratings for REGN

DateFirmActionFromTo
Nov 2020Morgan StanleyMaintainsEqual-Weight
Nov 2020Credit SuisseMaintainsOutperform
Nov 2020SVB LeerinkMaintainsOutperform

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

 

Related Articles (REGN)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Upgrades Health Care Price Target Analyst Ratings Movers Trading Ideas Best of Benzinga

Latest Ratings

StockFirmActionPT
PMTB of A SecuritiesMaintains18.5
IVRB of A SecuritiesMaintains3.0
EFCB of A SecuritiesMaintains15.5
NYMTB of A SecuritiesMaintains3.5
NLYB of A SecuritiesMaintains8.5
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com